Skip to main content
SpringerLink
Log in

Application of Anti-Ligand Antibodies to Inhibit Notch Signaling

  • Protocol
  • First Online:
Notch Signaling

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1187))

Abstract

Emerging evidence suggests that Notch signaling not only regulates biological processes during development but also participates in the pathogenesis of various diseases in adults, including tumor angiogenesis, hematopoietic malignancies, and cardiometabolic syndromes. Notch signaling involves several ligands and receptors that have unique and overlapping functions. Therefore, blocking function of a ligand or receptor with a neutralizing antibody is a useful approach to examine the specific role of each Notch component. In addition, administration of Notch signaling blocking antibodies in experimental animals offers important insights into clinical translation of Notch biology. In this chapter, we describe examples of in vitro and in vivo loss-of-function experiments with blockade of Notch ligands, particularly Delta-like ligand 4 (Dll4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. D’Souza B, Meloty-Kapella L, Weinmaster G (2010) Canonical and non-canonical Notch ligands. Curr Top Dev Biol 92:73–129

    Article  PubMed  Google Scholar 

  2. Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137:216–233

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Kovall RA, Blacklow SC (2010) Mechanistic insights into Notch receptor signaling from structural and biochemical studies. Curr Top Dev Biol 92:31–71

    Article  CAS  PubMed  Google Scholar 

  4. Cordle J, Johnson S, Tay JZ et al (2008) A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition. Nat Struct Mol Biol 15:849–857

    CAS  PubMed Central  PubMed  Google Scholar 

  5. Six E, Ndiaye D, Laabi Y et al (2003) The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. Proc Natl Acad Sci U S A 100:7638–7643

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Parr-Sturgess CA, Rushton DJ, Parkin ET (2010) Ectodomain shedding of the Notch ligand Jagged1 is mediated by ADAM17, but is not a lipid-raft-associated event. Biochem J 432:283–294

    CAS  PubMed  Google Scholar 

  7. Jarriault S, Brou C, Logeat F et al (1995) Signalling downstream of activated mammalian Notch. Nature 377:355–358

    CAS  PubMed  Google Scholar 

  8. Noguera-Troise I, Daly C, Papadopoulos NJ et al (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444:1032–1037

    CAS  PubMed  Google Scholar 

  9. Ridgway J, Zhang G, Wu Y et al (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444:1083–1087

    CAS  PubMed  Google Scholar 

  10. Real C, Remédio L, Caiado F et al (2011) Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis. PLoS One 6:e18323

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Jenkins DW, Ross S, Veldman-Jones M et al (2012) MEDI0639: A novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol Cancer Ther 11:1650–1660

    CAS  PubMed  Google Scholar 

  12. Fung E, Tung SM, Canner JP et al (2007) Delta-like 4 induces Notch signaling in macrophages: Implications for inflammation circulation 115:2948–2956

    Google Scholar 

  13. Fukuda D, Aikawa E, Swirski FK et al (2012) Notch ligand Delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proc Natl Acad Sci U S A 109:E1868–E1877

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Moriyama Y, Sekine C, Koyanagi A et al (2008) Delta-like 1 is essential for the maintenance of marginal zone B cells in normal mice but not in autoimmune mice. Int Immunol 20:763–773

    CAS  PubMed  Google Scholar 

  15. Lai PY, Tsai CB, Tseng MJ (2013) Active form Notch4 promotes the proliferation and differentiation of 3 T3-L1 preadipocytes. Biochem Biophys Res Commun 430:1132–1139

    CAS  PubMed  Google Scholar 

  16. Yamanda S, Ebihara S, Asada M et al (2009) Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade. Blood 113:3631–3639

    CAS  PubMed  Google Scholar 

  17. Oishi H, Sunamura M, Egawa S et al (2010) Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer. Pancreas 39:897–903

    CAS  PubMed  Google Scholar 

  18. Hemati N, Ross SE, Erickson RL et al (1997) Signaling pathways through which insulin regulates CCAAT/enhancer binding protein alpha (C/EBPalpha) phosphorylation and gene expression in 3 T3-L1 adipocytes. Correlation with GLUT4 gene expression. J Biol Chem 272:25913–25919

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by a National Institutes of Health grant R01HL107550 to M.A.

Author information

Authors and Affiliations

  1. The Center for Excellence in Vascular Biology, Brigham and Women’s Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, NRB-741J, Boston, MA, 02115, USA

    Jun-ichiro Koga

  2. The Center for Excellence in Vascular Biology and Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, NRB-741J, Boston, MA, 02115, USA

    Masanori Aikawa

Authors
  1. Jun-ichiro Koga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masanori Aikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masanori Aikawa .

Editor information

Editors and Affiliations

  1. Dept.of Molecular and Human Genetics, Program in Developmental Biology, Dept. of Neuroscience, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Howard Hughes Medical Institute, Baylor College of Medicine, Houston, Texas, USA

    Hugo J. Bellen

  2. Dept. of Molecular and Human Genetics, Program in Developmental Biology, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA

    Shinya Yamamoto

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this protocol

Cite this protocol

Koga, Ji., Aikawa, M. (2014). Application of Anti-Ligand Antibodies to Inhibit Notch Signaling. In: Bellen, H., Yamamoto, S. (eds) Notch Signaling. Methods in Molecular Biology, vol 1187. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1139-4_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1139-4_25

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1138-7

  • Online ISBN: 978-1-4939-1139-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation